18β-Glycyrrhetinic acid, and Carbenoxolone, which were used to pharmacologically manipulate LKB-1 dependent pathways and rescue HD toxicity in vivo, have also been reported to block gap junction activity [50]. This evidence concerns the gene STK11 and Huntington disease.